KR20250004744A - 보체-억제 하이브리드 단백질 - Google Patents

보체-억제 하이브리드 단백질 Download PDF

Info

Publication number
KR20250004744A
KR20250004744A KR1020247037353A KR20247037353A KR20250004744A KR 20250004744 A KR20250004744 A KR 20250004744A KR 1020247037353 A KR1020247037353 A KR 1020247037353A KR 20247037353 A KR20247037353 A KR 20247037353A KR 20250004744 A KR20250004744 A KR 20250004744A
Authority
KR
South Korea
Prior art keywords
amino acid
protein
acid sequence
human
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247037353A
Other languages
English (en)
Korean (ko)
Inventor
하일리 마
헝 리우
Original Assignee
롱바이오 파마 (수조우) 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 롱바이오 파마 (수조우) 컴퍼니 리미티드 filed Critical 롱바이오 파마 (수조우) 컴퍼니 리미티드
Publication of KR20250004744A publication Critical patent/KR20250004744A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247037353A 2022-04-11 2023-04-06 보체-억제 하이브리드 단백질 Pending KR20250004744A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210374811.2 2022-04-11
CN202210374811 2022-04-11
PCT/CN2023/086593 WO2023197930A1 (zh) 2022-04-11 2023-04-06 补体抑制杂合蛋白

Publications (1)

Publication Number Publication Date
KR20250004744A true KR20250004744A (ko) 2025-01-08

Family

ID=88312629

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247037353A Pending KR20250004744A (ko) 2022-04-11 2023-04-06 보체-억제 하이브리드 단백질

Country Status (6)

Country Link
US (1) US20250257106A1 (https=)
EP (1) EP4509521A4 (https=)
JP (1) JP2025512062A (https=)
KR (1) KR20250004744A (https=)
CN (1) CN116891533A (https=)
WO (1) WO2023197930A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025183519A1 (ko) 2024-02-29 2025-09-04 주식회사 엘지에너지솔루션 양극 활물질 재생 방법 및 이로부터 제조된 재생 양극 활물질

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024099320A1 (zh) * 2022-11-10 2024-05-16 天辰生物医药(苏州)有限公司 补体抑制杂合蛋白突变体及其抗体融合蛋白

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3066699A (en) * 1998-03-03 1999-09-20 Johns Hopkins University, The Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
WO2005069726A2 (en) * 2004-01-21 2005-08-04 Case Western Reserve University Hybrid and chimeric polypeptides that regulate activation of complement
ES2651521T3 (es) * 2011-12-01 2018-01-26 Innovent Biologics, Inc. Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos
US9540626B2 (en) * 2012-03-19 2017-01-10 The Trustees Of The University Of Pennsylvania Regulator of complement activation and uses thereof
CA3029106A1 (en) * 2016-06-28 2018-01-04 Universitat Ulm Complement inhibitors and uses thereof
GB201706808D0 (en) * 2017-04-28 2017-06-14 Univ Newcastle Modified complement proteins and uses thereof
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
EP3958901A4 (en) * 2019-04-24 2023-07-19 The Trustees of the University of Pennsylvania BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES
KR20250057830A (ko) * 2022-08-30 2025-04-29 롱바이오 파마 (수조우) 컴퍼니 리미티드 항-인간 보체 c5 항체 및 이의 융합 단백질

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025183519A1 (ko) 2024-02-29 2025-09-04 주식회사 엘지에너지솔루션 양극 활물질 재생 방법 및 이로부터 제조된 재생 양극 활물질

Also Published As

Publication number Publication date
EP4509521A4 (en) 2026-04-15
CN116891533A (zh) 2023-10-17
EP4509521A1 (en) 2025-02-19
JP2025512062A (ja) 2025-04-16
US20250257106A1 (en) 2025-08-14
WO2023197930A9 (zh) 2024-01-11
WO2023197930A1 (zh) 2023-10-19

Similar Documents

Publication Publication Date Title
AU2017263237B2 (en) GDF15 fusion proteins and uses thereof
US10689637B2 (en) Complement factor B analogs and their uses
JP2002543837A (ja) 組換えセトマンナン結合性レクチン
JP7505980B2 (ja) Ｃ３ｂ結合ポリペプチド
CN107709355A (zh) 单链cd40受体激动剂蛋白
CN109535243B (zh) 人肝细胞生长因子突变体及其应用
KR20250004744A (ko) 보체-억제 하이브리드 단백질
KR20180091097A (ko) 보체 활성화를 억제하기 위한 폴리펩티드
EP4582445A1 (en) Anti-human complement c5 antibody and fusion protein thereof
JP7814329B2 (ja) 抗ｌａｇ－３抗体とｉｌ－２とを含む融合タンパク質及びその使用
JPH09512706A (ja) ＫｉｔリガンドおよびＦＬＴ−３／ＦＬＫ−２リガンドの共有結合二量体
JPH09501822A (ja) 精製哺乳動物ｆｌｔ３リガンド並びにそのアゴニストおよびアンタゴニスト
EP4714979A1 (en) Biased complement inhibitory hybrid protein
CN113861291B (zh) VEGF-trap多肽及其应用
CN118955727A (zh) 偏向性补体抑制杂合蛋白
EP4617287A1 (en) Complement-inhibitory hybrid protein mutant and antibody fusion protein thereof
US9534038B2 (en) Isolated laminin-421
WO2023164266A2 (en) Dual checkpoint inhibitors and methods of using the same
WO2023025129A1 (zh) Gdf15融合蛋白及其用途
CN115551529A (zh) 增强房水流出并降低眼内压的方法
JP2003212791A (ja) ラミニン−６を含む、細胞接着活性及び／又は細胞運動活性調節用組成物
HK1037679A (en) Vascular endothelial growth factor 2
NZ616479B2 (en) Complement factor b analogs and their uses
CN1301761A (zh) 新的人趋化因子——巨噬细胞炎性蛋白、其编码序列及用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000